Novartis (NVS) Q3 results: Revenues: $12,172M (+10.5%); Innovative Medicines: $9,688M (+12.7%); Sandoz: $2,484M (+2.6%).
Net Income: $2,041M (+8.4%); EPS: $0.90 (+11.1%);
Non-GAAP Net Income: $3,212M (+4.8%); Non-GAAP EPS: $1.41 (+15.6%); CF
Ops: $10,007M (+4.1%).
Top sellers: Cosentyx: $937M (+25%); Entresto:
$430M (+59%); Promacta/Revolade: $380M (+29%); Tafinlar + Mekinist:
$345M (+19%); Kisqali: $123M (+71%); Jakavi: $279M (+13%); Lutathera:
$119M (+113%); Kymriah: $79M; Ilaris: $177M (+26%); Xolair: $299M
(+17%); Tasigna: $487M (+10%).
2019 Guidance: Net sales growth:
grow high-single digit from mid to high-single digit; Innovative
Medicines: grow high-single digit to low double digit from mid to
high-single digit; Sandoz: grow low-single digit from braodly in line to
low-single digit growth.
https://seekingalpha.com/news/3507603-novartis-beats-q3-consensus-guidance-revised-upwards
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.